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Abstract
Background: Cardiotoxicity in the form of cardiac arrhythmia, myocardial infarction, and angina-like symptoms are
not rare complications of fluoropyrimidines as 5-Fluorouracil (5FU) and capecitabine.
Discussion: Tas-102, a novel oral fluoropyrimidine, was recently approved by FDA for the treatment of advanced
and refractory colorectal cancer. Its unique mechanism of action doesn’t seem linked with cardiotoxicity in clinical
trials reported so far.
Summary: TAS 102 may represent one of the drugs of choice for patients with advanced colorectal cancer with
cardiac disease. This intriguing and clinically relevant issue is briefly examined.
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Background
Cardiotoxicity in the form of cardiac arrhythmia, myocar-
dial infarction, and angina-like symptoms are not rare
complications of fluoropyrimidines as 5-Fluorouracil
(5FU) and capecitabine (Table 1). The hallmark of cardio-
toxicity is the occurrence of coronary vasospasm leading
to the electrocardiographic and clinical manifestation of
myocardial ischemia. Meyer et al. [1], in a prospective
series of more than 400 patients treated with 5FU con-
tinuous infusion (ci), found an incidence of 3 % (9 cases
out of all observed patients) during the first course of
chemotherapy, and this was one of the first association of
type of 5FU administration and risk of cardiotoxicity, with
preexisting cardiac disease and concomitant cardiovascu-
lar drugs as main risk factors in these 9 patients. From
that publication, other series found evidence of cardiac
events occurrence during the administration of 5FU ci (or
capecitabine) for gastrointestinal malignancies. In particu-
lar, myocardial angina or cardiac infarction are the most
observed clinical manifestation of 5FU-related cardio-
toxicity, and other antimetabolites (e.g., raltitrexed) or
bolus 5FU administration could mitigate the risk of these
worrisome events [2, 3]. The exact pathophysiology of
these events is not well known, but a cardiac vasospasm
seems the main events associated with cardio- toxicity. It
has been postulated a role of the 5FU metabolites: in
particular 5FU is catabolized to alpha-fluoro-beta-alanine
(FBAL) and subsequently to fluoroacetate, the latter sus-
pect in particular as a cardiotoxic substance [4]. Recently,
Italian authors analyzed human cardiomyocytes and endo-
thelial cells to evaluate the effect of 5FU. They observed
autophagic features with reactive oxygen species (ROS)
elevation as an endothelial response and induction of a
senescent phenotype on both cell types treated with
5FU [5]. By these data and owing to the relative mis-
understanding of exact mechanisms involved in the
cardio-toxicity of 5FU, there is a rationale for using dif-
ferent inhibitors of thymidylate synthase (TS), com-
monly prescribed in clinical practice, in particular,
raltitrexed. Animal studies of myocardium damage after
5FU administration showed that multifocal hemor-
rhages, myofiber necrosis, inflammatory reactions in-
cluding perivascular involvement, pericarditis, valvulitis
and vascular changes, were observed. In particular, a
single high intravenous dose resulted in hemorrhagic
infarction of the ventricle walls, proximal spasms of the
coronary arteries and lethal outcome for animals within
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few hours. In contrast, repeated lower doses resulted in
left ventricular hypertrophy, concentric fibrous thickening
of the intima of coronary vessels and foci of necrotic
myocardial cells [6]. Whether the differences in histo-
pathological effects were due to different doses, is not
understood but could be the basis for an oral (chronic)
low dose of antimetabolites as TAS 102 and S-1.
Main text
TAS-102 is a new, recently labeled, oral fluoropyrimi-
dine used for chemorefractory colorectal cancer. It in-
creased overall survival by 2.4 months in patients with
metastatic colorectal cancer, pretreated with all active
drugs and biologics [7]. It has been developed in Asiatic
countries, and it has recently been approved in this set-
ting by FDA. TAS-102 consists of tri-fluorothymidine
(TFT) and an inhibitor of thymidine phosphorylase
(TPI). TFT, an analog of thymidine, exhibits two mecha-
nisms of anti-tumour actions: inhibition of TS, similarly
to the mechanism of action of 5FU, and the creation of
single-strand DNA breaks by incorporating the triphos-
phate form of TFT into DNA (Fig. 1). The concomitant
association of TFT and TFT and TPI (5-chloro-6- (2-
iminopyrrolidin-1-yl) methyl-2, 4 (1H 3H) -pyrimidine-
dione hydrochloride) showed an increase in the plasma
concentrations and anti-tumour activity of TFT for in-
hibition of TFT degeneration [8]. TAS-102 is an oral
anti-cancer drug consisting of TFT and TPI combined at
a molar ratio of 1: 0.5. The labeled schedule of TAS 102
is 35 mg/m2 given twice a day in a 28-day cycle orally
(2-week cycle of 5 days of treatment followed by a 2-day
rest period, and then a 14-day rest period).
Table 1 Cardiotoxicity of capecitabine, 5-Fluorouracil, TAS 102 and S1
Very common Common Uncommon Rare
Capecitabine Unstable angina pectoris, angina pectoris,
myocardial ischemia, atrial fibrillation,
cardiac arrhythmia, tachycardia, Palpitation
Ventricular fibrillation, QT prolongation,
torsade de pointes, bradycardia, vasospasm
5-fluorouracil Chest pain Myocardial infarction, myocardial ischemia,
cardiac arrhythmia, myocarditis, heart failure,
dilated cardiomyopathy
Cardiac arrest, sudden cardiac death
TAS-102 Myocardial infarction, myocardial ischemia,
chest pain, bradycardia, tachycardia
S1 Cardiac failure, acute myocardial infarction,
pericardial effusion, atrial fibrillation, angina pectoris,
cardiac fibrillation, tachycardia, palpitations
Fig. 1 TAS 102 mechanism of action compared to 5-FU
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We searched for phase I, phase II and randomized
phase III trials to evaluate if cardiovascular events were
reported and if any, which type of toxicity was observed
[7, 9–13]. Only studies reporting the current, labeled
scheduled of TAS 102 were considered. Among 4 phase
I studies, no cardiotoxic events were reported, including
3 single agent TAS 102 trials and a phase I study of a
combination of TAS 102 with a fixed dose of irinotecan
(121 patients overall). In the phase II trials comparing
TAS 102 (at the labeled dose) with placebo, 112 patients
were randomized but no cardiotoxic events were
reported yet. Finally in the pivotal phase III study by
Mayer et al. n = 3 and n = 2 cardiac events (cardiac is-
chemia) were recorded in the experimental and control
arms respectively, with no rate of cardiac arrhythmia
observed. The rate of cardiotoxicity in this trial is 0.5 %
that represents from 2 to 40-fold numerically less fre-
quent of that reported with 5FU in literature. A potential
limitation of our observation is that the patients who
had cardiotoxicity during previous treatments might
have been excluded from TAS102 trials, which enrolled
patients heavely pretreated with many previous lines of
therapies. Nevertheless, we think that the different
mechanism of action of TAS 102 compared with others
fluoropyrimydines might still explain the lack of cardio-
toxicity reported so far with this novel drug.
Different putative mechanisms of cardiotoxic-free
events in patients treated with TAS 102 could be
postulated:
1. A different autophagic induction of TAS 102
compared to 5FU. In Focaccetti et al. paper cited
above, autophagic features at the ultrastructural and
molecular levels, in particular in 5-FU exposed
cardiomyocytes and endothelial cells can be
observed. Conversely, TFT was more potent than
5FU, because it induces higher levels of cell death
and does not elicit an autophagic survival response
in the cancer cell lines [14].
2. A different oncological target (DNA damage and
synthesis) for TAS 102 itself compared to 5FU or
capecitabine: TF-TMP (tri-fluorothymidine
monophosphate) and TF-TTP (tri-fluorothymidine
triphosphate) vs FdUMP (fluorodeoxyuridine
monophosphate) and FdUTP (fluorodeoxyuridine
triphosphate).
3. The incorporation of FTD into DNA in tumor
tissues is significantly higher than its incorporation
into DNA in normal tissues, thus sparing
cardiovascular tissues [15].
4. TAS 102 is not catabolized by dihydropyridine
dehydrogenase (DPD), that is predominantly
expressed in the liver and inactivates more than
80 % of administered 5FU, with consequently
reduced the formation of FBAL [8]. This is
somewhat similar to that happen with S-1 that is a
combination of tegafur, gimeracil, and OXO. Because
of the significant DPD inhibition by gimeracil, FBAL
and other cardiotoxic 5FU catabolites (F-citrate)
levels are significantly lower than after capecitabine
or I.V. 5-FU administration, and less cardiotoxicity
can be expected [16]. F-citrate inhibits the Krebs
cycle by inhibition of aconitase, limiting the cellular
production of adenosine triphosphate (ATP).
Fluoroacetate is known to be highly cardiotoxic and
neurotoxic [17].
Conclusions
We can reasonably affirm that the new oral agent TAS
102, represent one of the true drugs of choice for
patients with advanced colorectal cancer with known
(pre-existing) cardiac disease or for those which manifest
cardiac complications during 5FU or capecitabine treat-
ment. It has several potential advantages over raltitrexed
(oral route and less renal toxicity) and S-1 that is not
still labeled for colorectal cancer in western countries.
Another possible benefit of TAS 102 is the possibility of
administering the drug to those subjects with known
DPD deficiency, so reducing the expected risk of severe
gastrointestinal toxicity. Combination studies with
other cytotoxics are in fiery, including biological agents.
Hematological toxicities represent the limiting event, but
with very low rate of febrile neutropenia. In the meanwhile
TAS 102 appear as one the most cardio-gentle nucleoside
analog available in clinical practice and may represent
the agent of choice when 5FU is indicated but rele-
vant comorbidities increase the cardiovascular risk.
Abbreviation
5FU, 5-Fluorouracil; ATP, adenosine triphosphate; ci, continuous infusion;
DPD, dihydropyridine dehydrogenase; FBAL, alpha-fluoro-beta-alanine;
FdUMP, fluorodeoxyuridine monophosphate; FdUTP, fluorodeoxyuridine
triphosphate; ROS, reactive oxygen species; TFT, tri-fluorothymidine;
TF-TMP, tri-fluorothymidine monophosphate; TF-TTP, tri-fluorothymidine
triphosphate; TPI, thymidine phosphorylase; TS, thymidylate synthase
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